Rheumatoid arthritis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• JAK 9
• TNF 9
• STAT3 0
• IL-6 2
• PI3K 0
• NLRP3 0
• CD19 18
• MAPK 0
• HIF-1 0
• NRF2 0
• mTOR 0
• IL-17 0
• STING 0
• AKT 0
• RANKL 0
• PPAR 0
• COX-2 0
• IL-1 0
• TLR4 0
• CD20 2
• TP53 0
• ERK 0
• PD-1 1
• SIRT1 0
• BCMA 7
• GLP-1 0
• MMP-9 0
• CTLA-4 1
• CTNNB1 0
• GPX4 0
• JNK 0
• SGLT2 1
• VEGF 1
• CD40 0
• HMGB1 0
• AMPK 0
• APOE 0
• AQP4 0
• CCR5 0
• FGFR 0
• IL-15 1
• METTL3 0
• PKM2 0
• TYK2 0
• CD38 1
• CGRP 0
• CXCR4 0
• IDO1 0
• PD-L1 0
• TIGIT 0
• BTK 0
• CD47 0
• EGFR 0
• HDAC 0
• IDH 0
• IL-23 0
• IL-4 0
• KEAP1 0
• MEK 0
• MYC 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  Regulation of type I interferon signaling by A20 (TNFAIP3) in autoimmune and autoinflammatory disease

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$55,114 awarded in fiscal year 2026· until Oct 2029

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, United States· until Oct 2028

• NIH NIAID · F31

  Genetic and cellular mechanisms underlying resistance to gammaherpesvirus infection

  University of Vermont & St Agric College· Burlington, United States· US$34,654 awarded in fiscal year 2026· until Sept 2028

• NIH NIAMS · UG3

  Axial TReatment Agent Options; Responsiveness of Disease to Inhibition of Numerous Anti-Rheumatic pathways in Youth (AxTRAORDINARY)

  Children's Hosp of Philadelphia· Philadelphia, United States· US$453,545 awarded in fiscal year 2026· until Aug 2027

• NIH NIAMS · K08

  Transcriptional regulation of synovial tissue-resident memory CD8 T cells

  University of California, San Diego· La Jolla, United States· US$100,345 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

  Queen Mary University of London· London, United Kingdom· EU contribution €4,793,228· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  BSSL TARGETING THERAPY TOWARDS NON-IMMUNOSUPPRESSIVE RA TREATMENT (SOL-116 - BEYOND)

  Lipum Ab· Umea, Sweden· EU contribution €7,995,375· until Jun 2029· 3 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  PRECISION-RA: Precision Immunotherapy for Rheumatoid Arthritis

  University of Bristol· Bristol, United Kingdom· EU contribution €150,000· until Nov 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies (My-NANO)

  Universiteit Gent· Gent, Belgium· EU contribution €2,499,750· until Apr 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Development of Armored targeted CAR-T cells for immune reset of T cell-mediated autoimmune diseases (iCARUS)

  Weizmann Institute of Science· Rehovot, Israel· EU contribution €150,000· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

10 of 416 running projects, newest first. Listed amounts together: US$230.9m + €169.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor

  NCT04530305· University Hospital, Montpellier· Updated 26 Oct 2026

  “Evolution of treatment sequencing for JAK inhibitors”Registry text, quoted unchanged. Source

• Terminated

  JAKPOT (JAK Inhibitors and Predictors of Outcome in RheumaToid Arthritis)

  NCT04084223· University Hospital, Montpellier· Updated 10 Jan 2025

  “Slower pace of enrollments”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis

  NCT05788705· Adel A.Gomaa· Source

• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

  NCT07137598· Hoffmann-La Roche· Source

• Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis

  NCT07674134· Centre Hospitalier Princesse Grace· Source

• Effect of JAK Inhibitor on Erosion Healing in RA

  NCT05955066· Chinese University of Hong Kong· Source

• Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

  NCT02759731· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 43
• Organoids 3
• Mendelian Randomization Analysis 98
• CRISPR-Cas Systems 1
• Gene Expression Profiling 122
• Sequence Analysis, RNA 17
• Exome Sequencing 2
• Proteomics 53
• Metabolomics 45
• Mass Spectrometry 8
• Flow Cytometry 33
• Immunohistochemistry 18
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 59
• Machine Learning 87
• Deep Learning 9
• Cohort Studies 162
• Genome-Wide Association Study 113

• Cell DiffErential Expression by Pooling (CellDEEP) highlights issues in differential gene expression in scRNA-seq.

  NAR Genom Bioinform, Oct 2026

• Small RNA sequencing identifies T cell-derived tsRNAs as novel biomarkers for diagnosis and clinical assessment of rheumatoid arthritis.

  Int Immunopharmacol, Aug 2026

• Single-Cell RNA Sequencing Revealed the Role of Interferon-Gamma Related Genes in Primary Sjögren's Syndrome.

  J Cell Mol Med, Aug 2026

• Immunological profiling of rheumatoid factor-positive primary Sjögren's syndrome by single-cell RNA sequencing.

  Front Immunol, Jun 2026

• Molecular classification of primary Sjögren's syndrome based on salivary gland omics.

  Arthritis Res Ther, Jun 2026

• Integrative Single-Cell RNA Sequencing and Spatial Transcriptomics Uncover Distinct Fibroblast-Macrophage Crosstalk in Human Hip Synovium Between Patients With Femoroacetabular Impingement and Osteoarthritis.

  Arthritis Rheumatol, May 2026

• Characteristics of peripheral blood neutrophil subsets in patients with primary Sjogren's syndrome based on single-cell RNA sequencing.

  Front Immunol, May 2026

• Integrated analysis of single-cell RNA sequencing, transcriptomics, and thermal proteome profiling identifies PLCG1 as the therapeutic target of isopimpinellin in treating rheumatoid arthritis.

  Cell Mol Biol Lett, Apr 2026

• Identification of rheumatoid arthritis manganese metabolism-related diagnostic biomarkers through bulk and single-cell RNA sequencing analysis.

  Clin Rheumatol, Mar 2026

• Revealing Metabolic Reprogramming Genes as Biomarkers of Rheumatoid Arthritis: A Bioinformatics Study Based on Ensemble Learning Approach and Single Cell RNA Sequencing.

  Endocr Metab Immune Disord Drug Targets, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.